LCTX Lineage Cell Therapeutics Inc

Price (delayed)

$1.215

Market cap

$302.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$269.35M

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 36
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 15

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house ...

Highlights
Lineage Cell Therapeutics's quick ratio has surged by 81% YoY and by 33% QoQ
The gross profit has soared by 58% YoY
LCTX's equity is down by 32% YoY but it is up by 21% QoQ
The debt has grown by 7% YoY

Key stats

What are the main financial stats of LCTX

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
1.25%
1 week
-8.65%
1 month
-14.44%
1 year
84.59%
YTD
-27.25%
QTD
-23.1%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$14.78M
Gross profit
$14.67M
Operating income
-$37.71M
Net income
-$64.21M
Gross margin
99.3%
Net margin
-434.4%
The net margin has plunged by 156% YoY
The operating income has dropped by 77% year-on-year and by 3% since the previous quarter
The gross profit has soared by 58% YoY
The revenue has soared by 55% YoY

Price vs fundamentals

How does LCTX's price correlate with its fundamentals

Growth

What is Lineage Cell Therapeutics's growth rate over time

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
5.62
P/S
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.23
LCTX's P/B is 41% below its last 4 quarters average of 9.4 but 29% above its 5-year quarterly average of 4.3
LCTX's equity is down by 32% YoY but it is up by 21% QoQ
The revenue has soared by 55% YoY
LCTX's price to sales (P/S) is 53% less than its 5-year quarterly average of 42.2 and 26% less than its last 4 quarters average of 26.9

Efficiency

How efficient is Lineage Cell Therapeutics business performance
LCTX's ROS has dropped by 177% year-on-year
Lineage Cell Therapeutics's ROIC has soared by 68% from the previous quarter
LCTX's return on equity is down by 16% since the previous quarter

Dividends

What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LCTX.

Financial health

How did Lineage Cell Therapeutics financials performed over time
LCTX's total assets is 93% greater than its total liabilities
Lineage Cell Therapeutics's quick ratio has surged by 81% YoY and by 33% QoQ
The current ratio has surged by 80% year-on-year and by 33% since the previous quarter
The debt is 96% less than the equity
The debt to equity has grown by 33% YoY but it has contracted by 20% from the previous quarter
LCTX's equity is down by 32% YoY but it is up by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.